The multiple sclerosis functional composite: a clinically meaningful measure of disability
- PMID: 20421572
- DOI: 10.1212/WNL.0b013e3181dbb571
The multiple sclerosis functional composite: a clinically meaningful measure of disability
Abstract
Background: The Multiple Sclerosis Functional Composite (MSFC) provides a focused and sensitive evaluation of disability in patients with multiple sclerosis (MS) that may be more responsive to change than that provided by the Expanded Disability Status Scale.
Expert clinical opinion: The MSFC is a 3-part quantitative instrument that measures arm, leg, and cognitive function with the 9-Hole Peg Test (arm/hand dexterity), the Timed 25-Foot Walk (leg function), and the Paced Auditory Serial Addition Test (3-second version, PASAT3; cognition). The MSFC has excellent test-retest reliability. Construct validity was supported by expected differences in scores between patients with primary or secondary progressive MS compared with relapsing-remitting MS. Concurrent validity was demonstrated by significant correlations with the Expanded Disability Status Scale, the Sickness Impact Profile, and the Short Form-36, particularly on the physical components of the latter 2 scales. MSFC scores also correlate with MRI changes. Limitations of the MSFC include practice effects with the PASAT and to a lesser extent the 9-Hole Peg Test, variations in the reference populations used to calculate Z-scores, and the lack of an accepted definition of a clinically meaningful change.
Future directions: Future research should be directed at adding a test that measures visual function (e.g., contrast acuity), at replacing the PASAT by a cognition test that has better measurement characteristics, and at developing methods to better understand the clinical relevance of changes in MSFC scores.
Similar articles
-
Binocular low-contrast letter acuity and the symbol digit modalities test improve the ability of the Multiple Sclerosis Functional Composite to predict disease in pediatric multiple sclerosis.Mult Scler Relat Disord. 2016 Nov;10:73-78. doi: 10.1016/j.msard.2016.08.012. Epub 2016 Aug 26. Mult Scler Relat Disord. 2016. PMID: 27919503 Free PMC article.
-
Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.Mult Scler. 2010 Feb;16(2):228-37. doi: 10.1177/1352458509354552. Epub 2009 Dec 22. Mult Scler. 2010. PMID: 20028710
-
[Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].Ideggyogy Sz. 2006 Nov 20;59(11-12):442-7. Ideggyogy Sz. 2006. PMID: 17203882 Hungarian.
-
The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials.Mult Scler. 2002 Oct;8(5):359-65. doi: 10.1191/1352458502ms845oa. Mult Scler. 2002. PMID: 12356200 Review.
-
Clinical outcome measures for research in multiple sclerosis.J Neuroophthalmol. 2001 Dec;21(4):296-301. doi: 10.1097/00041327-200112000-00014. J Neuroophthalmol. 2001. PMID: 11756863 Review.
Cited by
-
A phase II trial examining the safety and preliminary efficacy of repetitive transcranial magnetic stimulation (rTMS) for people living with multiple sclerosis.Trials. 2024 Sep 8;25(1):598. doi: 10.1186/s13063-024-08425-x. Trials. 2024. PMID: 39245707 Free PMC article.
-
Advanced neuroimaging techniques to explore the effects of motor and cognitive rehabilitation in multiple sclerosis.J Neurol. 2024 Jul;271(7):3806-3848. doi: 10.1007/s00415-024-12395-0. Epub 2024 May 1. J Neurol. 2024. PMID: 38691168 Review.
-
Beneficial Effects of Plant Oils Supplementation on Multiple Sclerosis: A Comprehensive Review of Clinical and Experimental Studies.Nutrients. 2023 Nov 18;15(22):4827. doi: 10.3390/nu15224827. Nutrients. 2023. PMID: 38004221 Free PMC article. Review.
-
Diet-induced changes in functional disability are mediated by fatigue in relapsing-remitting multiple sclerosis: A secondary analysis of the WAVES randomized parallel-arm trial.Mult Scler J Exp Transl Clin. 2023 Oct 30;9(4):20552173231209147. doi: 10.1177/20552173231209147. eCollection 2023 Oct-Dec. Mult Scler J Exp Transl Clin. 2023. PMID: 37916030 Free PMC article.
-
Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease.CNS Drugs. 2023 Jan;37(1):69-92. doi: 10.1007/s40263-022-00977-3. Epub 2023 Jan 4. CNS Drugs. 2023. PMID: 36598730 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical